Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 trial of ICP-488 in moderate-to-severe plaque psoriasis has completed, reporting efficacy, safety, pharmacokinetics and pharmacodyna…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]
Akeso reports that the Phase 2 clinical study of AK101 in moderate to severe plaque psoriasis has completed. The summary does not provide ef…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis [Phase 3]
Phase 3 clinical trial update for HS-20137 in participants with moderate-to-severe plaque psoriasis; the study status is NOT_YET_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
This document reports the completion of a Phase 3 clinical trial evaluating AK111 for moderate to severe plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis [Phase 2]
A Phase 2 clinical trial update reports the completion of a Phase 2 study evaluating jaktinib in participants with plaque psoriasis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating the efficacy and safety of SHR-1314 in pediatric patients aged 6 to less than 18 with moderate-to-severe plaque pso…
-
FDA approval · 2025-02-12FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis [Phase 1]
This update notes the completion of a Phase 1 study of S011806 (DC-806 or LY4100504) in healthy adults and participants with chronic plaque …
-
CLINICAL_TRIALS research · 2025-01-31Clinical Trial Update: Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
A real-world study of Xeligekimab for moderate to severe plaque psoriasis is planned and not yet recruiting, sponsored by Chongqing Genrix B…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
This clinical trial aims to evaluate the effects of switching from a biologic treatment to tildrakizumab in adults with moderate-to-severe p…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information
A study is being developed to build a diagnostic model for psoriasis and psoriatic arthritis based on multidimensional nail information; the…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 trial update for AK111 injection in moderate-to-severe plaque psoriasis; the study has completed, but efficacy and safety results ar…
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis [Phase 4]
Phase IV trial evaluating the efficacy and safety of Vunakizumab in adults with moderate-to-severe plaque psoriasis; the study is currently …
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis [Phase 2]
Phase 2 study of KBL697 in adults with moderate plaque psoriasis has completed, with efficacy and safety results to be reported.
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis [Phase 3]
An open-label extension trial of roflumilast (PDE4 inhibitor) for chronic plaque psoriasis has completed Phase 3 testing, focusing on long-t…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of TLL018 for moderate-to-severe plaque psoriasis has completed.
-
FDA approval · 2024-12-26FDA Approved: WEZLANA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental Biologics License Application for WEZLANA (ustekinumab-auub) submitted by Nuvaila Limited.
-
FDA approval · 2024-12-20FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC. This action confirms additional regul…
-
FDA approval · 2024-12-18FDA Approved: IDACIO — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for IDACIO (adalimumab-aacf) from Fresenius Kabi USA, LLC.
-
FDA approval · 2024-12-17FDA Approved: STEQEYMA — Original Application (CELLTRION USA, Inc.)
FDA approved STEQEYMA (ustekinumab-stba) from Celltrion USA as a biosimilar to ustekinumab under an original biologics license application. …
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating the efficacy and safety of bimekizumab in adults with moderate to severe chronic plaque psoriasis; the study has co…
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
A real-world study evaluating tuberculosis incidence in patients with ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis treat…
-
FDA approval · 2024-11-29FDA Approved: YESINTEK — Original Application (Biocon Biologics Inc.)
FDA approved Yesintek (ustekinumab) from Biocon Biologics Inc. under an Original Application. It covers the established ustekinumab indicati…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis [Phase 2]
A Phase 2 trial evaluating MP1032 for chronic plaque psoriasis has completed, and results have been posted on ClinicalTrials.gov.
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
An observational study evaluating the real-world safety and effectiveness of deucravacitinib (Sotyktu) in Korean adults with moderate-to-sev…